Curated News
By: NewsRamp Editorial Staff
July 22, 2026
Quantum BioPharma Tackles MS and Alcohol Impairment with Novel Pipeline
TLDR
- Quantum BioPharma's Lucid-MS offers a novel approach to MS, potentially capturing market share from existing therapies.
- Lucid-MS is a patented new chemical entity for MS, with phase 2 development supported by an imaging collaboration with Massachusetts General Hospital.
- Quantum BioPharma aims to improve life for millions with neurological disorders through innovative MS and alcohol intoxication treatments.
- Unbuzzd, a supplement from Quantum BioPharma, supports alcohol metabolism to reduce hangover effects.
Impact - Why it Matters
This news matters because multiple sclerosis affects nearly 3 million people worldwide, and current treatments often fail to repair nerve damage or prevent disability progression. Quantum BioPharma's Lucid-MS could offer a game-changing approach by promoting remyelination, potentially improving quality of life for millions. Additionally, the unbuzzd supplement addresses the widespread issue of alcohol hangover and intoxication, offering a science-backed solution for consumers. Together, these developments highlight a company targeting both chronic neurological disease and acute brain health, with implications for patients, investors, and public health.
Summary
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing two innovative approaches to neurological disorders that affect millions worldwide. The company's lead candidate, Lucid-MS, is a patented new chemical entity designed to treat multiple sclerosis (MS) by targeting remyelination—a fundamentally different mechanism from existing therapies that primarily focus on immune modulation. With approximately 2.9 million people living with MS globally, including one million in the United States, there is a critical need for treatments that can repair nerve damage and slow disease progression. Quantum BioPharma is supporting Lucid-MS's phase 2 development through an ongoing imaging collaboration with Massachusetts General Hospital, leveraging advanced MRI techniques to assess remyelination in patients.
In addition to its MS pipeline, Quantum BioPharma has developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. This product addresses a widespread consumer need, with the global hangover cure market projected to grow significantly. The company's dual focus on both chronic neurological disease and acute alcohol-related impairment reflects a strategic approach to addressing brain health across different stages and conditions.
The news highlights Quantum BioPharma's commitment to tackling areas of high unmet medical need, backed by partnerships with leading research institutions. For investors and patients alike, the progress of Lucid-MS and the commercial potential of unbuzzd represent significant milestones. The company's newsroom provides ongoing updates for those interested in following QNTM's developments.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Quantum BioPharma Tackles MS and Alcohol Impairment with Novel Pipeline
